Intellia Therapeutics NTLA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Intellia Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's retained earnings?
- Intellia Therapeutics (NTLA) reported retained earnings of -$2.69B in Q1 2026.
- How has Intellia Therapeutics's retained earnings changed year-over-year?
- Intellia Therapeutics's retained earnings decreased by 17.2% year-over-year, from -$2.29B to -$2.69B.
- What is the long-term trend for Intellia Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Intellia Therapeutics's retained earnings has grown at a 42.9% compound annual growth rate (CAGR), from -$435.11M to -$2.59B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.